Cytogenetics in the management of acute myeloid leukemia and histiocytic/dendritic cell neoplasms: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH)

Curr Res Transl Med. 2023 Oct-Dec;71(4):103421. doi: 10.1016/j.retram.2023.103421. Epub 2023 Oct 16.

Abstract

Genetic data are becoming increasingly essential in the management of hematological neoplasms as shown by two classifications published in 2022: the 5th edition of the World Health Organization Classification of Hematolymphoid Tumours and the International Consensus Classification of Myeloid Neoplasms and Acute Leukemias. Genetic data are particularly important for acute myeloid leukemias (AMLs) because their boundaries with myelodysplastic neoplasms seem to be gradually blurring. The first objective of this review is to present the latest updates on the most common cytogenetic abnormalities in AMLs while highlighting the pitfalls and difficulties that can be encountered in the event of cryptic or difficult-to-detect karyotype abnormalities. The second objective is to enhance the role of cytogenetics among all the new technologies available in 2023 for the diagnosis and management of AML.

Keywords: Acute myeloid leukemia; Cytogenetic abnormalities; Histiocytic/dendritic cell neoplasms; Prognosis.

Publication types

  • Review
  • Practice Guideline

MeSH terms

  • Chromosome Aberrations
  • Cytogenetic Analysis
  • Dendritic Cells / pathology
  • Hematology
  • Histiocytosis* / diagnosis
  • Histiocytosis* / genetics
  • Histiocytosis* / therapy
  • Humans
  • Leukemia, Myeloid, Acute* / diagnosis
  • Leukemia, Myeloid, Acute* / genetics
  • Leukemia, Myeloid, Acute* / therapy